# Suzetrigine in Total Hip Arthroplasty

> **NCT07226700** · PHASE3 · RECRUITING · sponsor: **Hospital for Special Surgery, New York** · enrollment: 210 (estimated)

## Conditions studied

- Total Hip Arthroplasty (THA)
- Total Hip Arthroplasty \(THA\)
- Total Hip Replacement
- Total Hip Replacement Surgery
- Total Hip Replacements
- Total Hip Replacement Arthroplasty
- Suzetrigine
- Pain Management
- Pain
- Nav 1.8
- JOURNAVX
- Opioid Cessation
- Opioid Consumption, Postoperative
- Multimodal Analgesia
- Randomized Controlled Trial
- Randomized Controlled Study
- Randomized Controlled Trials

## Interventions

- **DRUG:** Suzetrigine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07226700
- **Lead sponsor:** Hospital for Special Surgery, New York
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-03
- **Primary completion:** 2027-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07226700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07226700, "Suzetrigine in Total Hip Arthroplasty". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT07226700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*